PACELF
Pacifc Programme to Eliminate Lymphatic Filariasis
How you can help Mailing List Contact Us
.
About PacElf
Our Work
Progress
Country Programmes
Annual Reports
Mosquito Newsletter
Related Links
Frequently Asked Questions
Publications
Publications
GA4 Meeting
Home
.

Progress PacELF

PacELF Highlights 2005

1.  Administration and office management

- PacELF Office Team in 2005

Dr Kazuyo Ichimori (Team leader, WHO), Mr Yoshio Furuya (UNV), Ms Hiroko Watahashi (UNV), Ms Kazumi Nakamoto (Senior JOCV), Ms Martha Colata (WHO), Ms Emma Gibbons (WHO)

- Japanese Volunteers (JOCV) in Fiji, Tonga, and Vanuatu supported PacELF country programmes.

2.  Sub-regional stock and supply system

- JICA provided ICT test kits and DEC tablets.

- Albendazole tablets were donated by GSK.

- 91,000 ICT test cards, 27,890,000 DEC tablets, 1,709,700 albendazole tablets were distributed to countries from PacELF warehouse in Fiji.

3.  Data information and communication network

- The PacELF Website (www.pacelf.org) was updated regularly

4.  Advocacy document Guidelines

- PacELF Our Work 2004 (Progress Report of January-December 2004)

- PacELF 7th Annual Meeting Report 2005

- PacELF Mosquito control poster/leaflets

- PacELF calendar 2006

5.  Training and meetings

- PacELF 7th annual meeting was held in Suva, Fiji, from 22nd to 26th of August 2005.

6.  Technical Collaboration and Scientific Basis

- PacELF monitoring and evaluation group with Emory University LF Support Center, CDC, and Institute Louis Malarde

- Consultants and collaborators

Mr. Jonathan King, Dr Patricia Graves, Dr Jeffery Hii, Jeffery Talbot and Kosuke Nakamura worked in the PacELF member countries.

7.  PacCARE (PacELF Coordination and Programme Review Group)

- PacCARE 7th meeting was held in Suva, Fiji, on August 26th 2005.

- Country activities were reviewed. 

8.  Implementations of the country activities

- Cook Islands, Niue, and Vanuatu conducted their final prevalence survey to assess the impact of 5 MDAs.

- MDA was conducted in eight countries
(6th MDA: French Polynesia. 5th MDA: American Samoa, Kiribati, Tonga, and Tuvalu. 4th MDA: Fiji and Wallis & Futuna. 1st MDA: Papua New Guinea.)

9.  Partnership and External Relations

- GlaxoSmithKline (GSK) provided financial support.

- The Japanese Government granted Japan’s Grant Assistance for Grassroots Project “GGP” funding through the Embassy of Japan in Fiji.

- JICA supported the programme by supplying ICT test kits and DEC tablets, and through JOCV volunteers.

- UNDP supported the programme by providing United Nations Volunteer (UNV).

Progress of Country Programme (% Filarial Antigenaemia and % MDA Treatment Coverage) as of 2005

.Country 1997 1998 1999 2000 2001

2002

2003 2004 2005
Non Endemic

6 countries

GUM Prevalence rate 0.0%
154,805
NAU Prevalence rate 0.3% 1.7%
10,065
NMI
Prevalence rate 0.0%
69,221
PTC Prevalence rate 0.0%
48
SOL Prevalence rate 0.0% 0.3%
409,042
TOK Prevalence rate *0.1%
1,537
Partial Endemic
5 countries
FSM

Prevalence rate

. .0.2%. .
107,008
MAR Prevalence rate . . . .0.1%
50,840 M
NEC Prevalence rate 0.5%
196,836
PAL Prevalence rate . . . 0.4%.
19,129 .
WAF Prevalence rate . . 0.7% 0%.
14,944 MDA - April 60% 65% 66% 57%
Pacific Islands Endemic

11 countries
AMS Prevalence rate 16.5% 11.5% 13.5%.
57,881 MDA- Sep 24% 52% 50% 70% 65% 66%
COK Prevalence rate 8.6% 0.4% 1.27%
13,905 MDA - Jun. 62% 64% 98% 88% 93%
FIJ Prevalence rate 16.6%. 14.0%. 11.40%.
776,173 MDA - Sep 70% 62% 69% 70%
FRP Prevalence rate 13.8%
252,900 MDA - Mar 93% 95% 93% 90% 93% 104%
KIR Prevalence rate. 1.7%
84,494 MDA - Aug 60% 46% 49% 67% 87%
NIU Prevalence rate 3.1% 1.3% 0.2%
1,639 MDA - Mar 94% 99% 82% 78% 85%
PNG Prevalence rate 6.0% 31.01%**
5,190,786 MDA 84%
SMA Prevalence rate 4.5% 4.5% 1.1%
176,848 MDA - Oct. 90% 57% 68% 60% 80%
TNG Prevalence rate 2.7% . 2.5%
97,784 MDA - Mar 79% 84% 91% 86% 85%
TUV Prevalence rate 22.3% . . 16,2% 12.1%
9,561 MDA - Sep 81% 47% 83% 84% on going
VAN Prevalence rate 4.8% 8.0% on going
186,678 MDA - Jun 83% 84% 84% 87% 85%


* : non resident
**: conducted in MilneBay Province

......

Baseline Assessment (A)

..

MDA

....

Midterm Assessment (B)

Final Assessment (C)


Lymphatic Filariasis • Waqaqa • Big Leg • Filariasis • Aoraki Man Te Mata • Rektel a Rekas • Mumu Tutupa • Mwirara • Filariasis Pwuur • Moko Pata • Kinal • Te Fu'aa • Va'e Fua • Eke'Eke • Mumu Tutupa • fe'fee • Va'e Fua • Legi Biki